<DOC>
	<DOCNO>NCT00607802</DOCNO>
	<brief_summary>RATIONALE : White blood cell donor may able kill cancer cell patient cancer . PURPOSE : This clinical trial study side effect donor white blood cell infusion treat patient metastatic unresectable cancer .</brief_summary>
	<brief_title>Donor White Blood Cell Infusion Treating Patients With Metastatic Unresectable Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety white blood cell infusion patient metastatic unresectable cancer . Secondary - Determine efficacy therapy patient . OUTLINE : Patients receive allogeneic white blood cell infusion daily 5-10 infusion . Patients undergo blood sample collection periodically correlative laboratory study . The sample evaluate vitro white cell kill assay first infusion , immediately first infusion , day 2 , immediately last infusion ass vitro cancer cell kill activity . Chimerism study perform first infusion , immediately first infusion , day 2 7 . Complete chimerism assay short tandem repeat analysis use PCR . Patients readily accessible tumor tissue ( e.g. , cervical axillary lymph node subcutaneous tumor nodule ) may also undergo biopsy first week treatment demonstrate presence absence tumor infiltrate granulocyte . After completion study therapy , patient follow periodically 3 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm malignancy Metastatic unresectable disease Standard curative palliative measure exist longer effective Measurable nonmeasurable disease Measurable disease define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Nonmeasurable disease define lesion ( include small lesion truly nonmeasurable lesion ) , include follow : Bone lesion Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion No brain metastasis Healthy blood donor available meeting follow criterion : Willing include White Cell Donor Registry create study Willing undergo granulocyte apheresis American Red Cross ABO compatible patient HLAmismatched patient Demonstrates ≥ 60 % cytotoxic killing activity ( CKA ) determine vitro white cell kill assay Less 60 % CKA allow deem suitable investigator PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 4 month ANC ≥ 1,000/µL Platelet count &gt; 100,000/µL ( platelet transfusion independent ) Serum bilirubin ≤ 2 mg/dL AST ALT &lt; 3 time upper limit normal Serum creatinine ≤ 2 mg/dL No uncontrolled diabetes mellitus No myocardial infarction within past 30 day No active serious infection No HIV infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Negative panel reactive antibody test ( i.e. , absence serum HLA antibody ) PRIOR CONCURRENT THERAPY : No prior fludarabine phosphate No prior stem cell transplantation At least 4 week since prior medical therapy , radiotherapy , surgery More 30 day since prior immunosuppressive agent steroid</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>